Related Experiment Video

Updated: Dec 31, 2025

Modeling Charcot-Marie-Tooth Disease In Vitro by Transfecting Mouse Primary Motoneurons
07:43

Modeling Charcot-Marie-Tooth Disease In Vitro by Transfecting Mouse Primary Motoneurons

Published on: January 7, 2019

7.3K

Are we prepared for clinical trials in Charcot-Marie-Tooth disease?

A M Rossor1, M E Shy2, M M Reilly1

  • 1Department of Neuromuscular Diseases, University College London, Queen Square Institute of Neurology, London, United Kingdom.

Brain Research
|January 4, 2020
PubMed

Insights

Developing treatments for Charcot-Marie-Tooth type 1A (CMT1A) faces challenges due to the disease's slow progression. Researchers are learning from past trials to improve future clinical studies and outcome measures for CMT1A therapies.

Area of Science:

  • Neurology
  • Clinical Trials
  • Biomedical Research

Background:

  • Charcot-Marie-Tooth disease (CMT), particularly CMT type 1A (CMT1A), is a slowly progressive neuropathy with limited treatment options.
  • Several randomized, double-blind, placebo-controlled trials for CMT1A have been conducted, yielding valuable insights despite not meeting primary endpoints.

Purpose of the Study:

  • To review the challenges in conducting clinical trials for slowly progressive neurological disorders like CMT1A.
  • To summarize existing and emerging outcome measures for assessing therapeutic efficacy in CMT1A.

Main Methods:

  • Review of completed and ongoing clinical trials for CMT1A.
  • Analysis of various outcome measures used in CMT research, including clinical, functional, and patient-reported assessments.
  • Evaluation of biomarkers for disease burden and treatment response.

Main Results:

  • Past CMT1A trials, while negative for primary outcomes, have generated crucial data for future trial design and natural history studies.
  • A diverse array of CMT-specific outcome measures has been developed, encompassing clinical assessments, functional tests, patient-reported outcomes, and biomarkers.
  • No single outcome measure currently integrates all desired qualities: clinical relevance, sensitivity, and reproducibility.

Conclusions:

  • Conducting clinical trials for slowly progressive diseases like CMT1A requires carefully selected, sensitive, and reproducible outcome measures.
  • The development of comprehensive outcome measures is critical for advancing therapeutic development in CMT1A.
  • Continued research into novel and validated outcome measures is essential for future CMT1A clinical trials.
Keywords:
Charcot-Marie-Tooth diseaseClinical trialOutcome measures

More Related Videos

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.5K
Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

33.0K

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.1K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
888
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
285
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K